We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Pegcetacoplan

News List

Pegcetacoplan safe and effective in paroxysmal nocturnal haemoglobinuria trial europeanpharmaceuticalreview
May 27, 2021
In a Phase III study pegcetacoplan resulted in 86 percent of treatment-naïve paroxysmal nocturnal haemoglobinuria (PNH) patients achieving haemoglobin stabilisation.
Apellis enters drug development and commercialisation deal with Sobi pharmaceutical-technology
October 29, 2020
Apellis Pharmaceuticals has entered into a strategic collaboration with Swedish Orphan Biovitrum (Sobi) to fast-track the advancement of systemic pegcetacoplan to treat multiple rare diseases with high unmet need.
Apellis to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria americanpharmaceuticalreview
May 27, 2020
Apellis Pharmaceuticals announced plans to submit a New Drug Application (NDA) for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the second half of 2020.